Description
AstraZeneca: Pipeline Diversification, Innovation & Geographic Market Expansion Powering Our ‘Outperform’ Rating!
AstraZeneca has reported its first quarter 2025 financial results, revealing a robust performance marked by a 10% increase in total revenue. The pharmaceutical giant’s growth was driven by rising demand for its innovative medicines, with core operating profit up by 12% and core EPS rising by 21%. This performance was partially bolstered by favorable tax settlements. The company secured 13 regulatory approvals across key regions for its diverse portfolio, emphasizing its ongoing focus on delivering high-value treatments and novel molecular entities (NMEs).
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!